Epidemiology and Antifungal Susceptibility of Bloodstream Candida Isolates in Quebec: Report on 453 Cases between 2003 and 2005
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Between May 2003 and April 2005, a population‐based surveillance of Candida bloodstream infections was conducted in Quebec. A total of 453 episodes of candidemia (464 yeast isolates) from 54 participating hospitals were studied. RESULTS: The annual incidence rate was three per 100,000 population. Global hospital mortality was 38%. The most common predisposing factors were the presence of an intravascular catheter (80%), use of antibacterial therapy (67%), stay in an intensive care unit (49%), use of parenteral nutrition (32%) and intra‐abdominal surgery (31%). Fluconazole alone or in association with other antifungals was used for treatment in over 80% of cases. Candida albicans comprised 62% of isolates, followed by Candida glabrata (17%), Candida parapsilosis (9%), Candida tropicalis (5%), Candida lusitaniae (3%) and Candida krusei (3%). Of the 288 C albicans isolates, seven (2%) were resistant to flucytosine, one to fluconazole and none to itraconazole or voriconazole. Of the 75 non‐C albicans species isolates with reduced susceptibility to fluconazole (minimum inhibitory concentration [MIC] 16 μg/mL or greater), none were susceptible to itraconazole (MIC 0.12 mg/L or lower), whereas 71 (95%) were susceptible to voriconazole (MIC 1 μg/mL or lower). However, only five of 12 (42%) fluconazole‐resistant isolates were susceptible to voriconazole. Posaconazole, ravuconazole and caspofungin displayed a broad spectrum of activity against these isolates, with MICs of 1 mg/L or lower in 56%, 92% and 100% of isolates, respectively. Overall, a correlation (r 2>0.87) was observed among increasing fluconazole MICs and the geometric mean MICs of itraconazole, voriconazole, posaconazole and ravuconazole. CONCLUSIONS: These surveillance results when compared with those of the 1993 to 1995 survey confirm little variation in the distribution of species causing invasive Candida infection over a 10‐year period in Quebec, as well as the continuous excellent overall in vitro activity of fluconazole.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444 · cited 4×
“At the present time, concerns over the inability of the CLSI method M27-A to adequately detect amphotericin B resistance remain, and the clinical significance of in vitro resistance to amphotericin B has yet to be established (21,22,25,32).”
BackgroundMethodInfluentialMorgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437
Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385 · cited 2×
“Overall, rates reported in Canadian studies are lower than those from the United States which are, on average, two to three times higher (7,8,11).”
BackgroundKrogh-Madsen, M., Arendrup, M. C., Heslet, L., & Knudsen, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/500939 · Cited by 201 · cited 1×
“These species were previously observed to be innately less susceptible in vitro to amphotericin B, and Goldman et al (34) have reported that a significantly better response to C krusei infections was obtained when patients were treated with amphotericin B dosages greater than 1 mg/kg/day compared with patients receivi…”
BackgroundDetection of amphotericin B-resistant Candida isolates in a broth-based system
Rex, J. H., Cooper, C. R., Merz, W. G., Galgiani, J. N., & Anaissie, E. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.4.906 · Cited by 198
Increasing Incidence of Candidemia: Results from a 20-Year Nationwide Study in Iceland
Ásmundsdóttir, L. R., Erlendsdóttir, H., & Gottfredsson, M. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.9.3489-3492.2002 · Cited by 188 · cited 1×
“Population-based studies (6-8,10-13) in North America and Europe have reported annual incidence rates ranging between two to 10 per 100,000 population.”
BackgroundRex, J. H., Nelson, P. W., Paetznick, V. L., Lozano-Chiu, M., Espinel-Ingroff, A., & Anaissie, E. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.1.129 · Cited by 167 · cited 2×
“These two isolates exhibiting ‘low-high’ MICs at 24 h and 48 h of incubation were reported as susceptible in accordance with recommendations from two in vivo investigations of this phenomenon (37,38).”
BackgroundResultArthington-Skaggs, B. A., Warnock, D. W., & Morrison, C. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2081-2085.2000 · Cited by 142 · cited 2×
“These two isolates exhibiting ‘low-high’ MICs at 24 h and 48 h of incubation were reported as susceptible in accordance with recommendations from two in vivo investigations of this phenomenon (37,38).”
BackgroundResultSt-Germain, G., Laverdière, M., Pelletier, R., Bourgault, A.-M., Libman, M., Lemieux, C., & Noël, G. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.949-953.2001 · Cited by 134 · cited 5×
“4% and is essentially the same as that previously observed in our 1996 to 1998 survey (3%) (18).”
BackgroundResultInfluentialSelf-citationMacphail, G. L. P., Taylor, G. D., Buchanan‐Chell, M., Ross, C., Wilson, S., & Kureishi, A. (2002) · Mycoses · doi:10.1046/j.1439-0507.2002.00741.x · Cited by 119 · cited 1×
“the fact that most studies have been performed in single centres (14-17).”
BackgroundPark, B. J., Arthington-Skaggs, B. A., Hajjeh, R. A., Iqbal, N., Ciblak, M. A., Lee-Yang, W., Hairston, M. D., Phelan, M., Plikaytis, B. D., Sofair, A. N., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1287-1292.2006 · Cited by 113 · cited 3×
“To date, there have been few population-based studies (15,32) reporting on the activity of these agents against Candida bloodstream isolates.”
BackgroundMethodResultConstant Low Rate of Fungemia in Norway, 1991 to 1996
Sandven, P., Bevanger, L., Digranes, A., Gaustad, P., Haukland, H. H., Steinbakk, M., & The Norwegian Yeast Study Group (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.12.3455-3459.1998 · Cited by 82
Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01551-06 · Cited by 77
Cited by
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Changes in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Metadata
- Authors
- St-Germain, G., Laverdière, M., Pelletier, R., René, P., Bourgault, A.-M., Lemieux, C., & Libman, M.
- Venue
- Canadian Journal of Infectious Diseases and Medical Microbiology
- Publisher
- Wiley
- Published
- 2007-08-09
- Volume
- 19
- Issue
- 1
- Pages
- 55-62
- ISSN
- 1180-2332 (ISSN-L)
- 1712-9532
- 1918-1493
- OpenAlex
- W1518372890
- Cited by
- 60
- References
- 17
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.